PharmacoEconomics & Outcomes News 792, p29 - 2 Dec 2017 Systemic scleroderma has high economic burden Systemic scleroderma (SSc) appears to be associated with a high economic burden due to unemployment and reduced work productivity, according to findings of the Australian Scleroderma Cohort Study published in Rheumatology. In this study conducted across four states of Australia between December 2007 and January 2016, 476 patients with systemic scleroderma completed four questionnaires: the Workers’ Productivity and Activity Impairment Questionnaire, a customised questionnaire on employment, the Medical Outcome Short Form 36-item (SF-36) health survey, and Patient-Reported Outcomes Measurement Information System 29 (PROMIS 29). Work-related costs for unemployment and lost productivity were estimated from a societal perspective. Only 55.2% of respondents under 65 years of age were employed. Those who were unemployed were older than patients with employment (57.1 vs 53.7 years; p<0.001) and had a longer disease duration (16.2 vs 14.9 years; p=0.01). The mean age at which patients became unemployed was 13.2 years below the average age of retirement in Australia. Among employed patients who worked during the previous week, 16.0% reported systemic scleroderma- related absenteeism totalling 32.9% of the working week, and reduced work productivity (presenteeism) accounted for 22% of the week. Estimated annual costs due to unemployment and reduced productivity totalled $67 595.40 per patient. Estimated annual costs for lost productivity in employed patients were $8024.20 per patient. "SSc is associated with considerable unemployment and reduced productivity, which in turn are associated ** with poor HRQoL and a substantial economic burden to employers and the wider society," concluded the investigators. * 2015 Australian dollars ** health-related quality of life Morrisroe K, et al. Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life. Rheumatology : 9 Oct 2017. Available from: URL: http://doi.org/10.1093/rheumatology/kex362 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera